202 related articles for article (PubMed ID: 17638399)
1. Effect of dissociative experiences on drug treatment of panic disorder.
Gulsun M; Doruk A; Uzun O; Turkbay T; Ozsahin A
Clin Drug Investig; 2007; 27(8):583-90. PubMed ID: 17638399
[TBL] [Abstract][Full Text] [Related]
2. Facing the fear--clinical and neural effects of cognitive behavioural and pharmacotherapy in panic disorder with agoraphobia.
Liebscher C; Wittmann A; Gechter J; Schlagenhauf F; Lueken U; Plag J; Straube B; Pfleiderer B; Fehm L; Gerlach AL; Kircher T; Fydrich T; Deckert J; Wittchen HU; Heinz A; Arolt V; Ströhle A
Eur Neuropsychopharmacol; 2016 Mar; 26(3):431-44. PubMed ID: 26837851
[TBL] [Abstract][Full Text] [Related]
3. Influence of personality disorder on the treatment of panic disorder--comparison study.
Prasko J; Houbová P; Novák T; Záleský R; Espa-Cervená K; Pasková B; Vyskocilová J
Neuro Endocrinol Lett; 2005 Dec; 26(6):667-74. PubMed ID: 16380683
[TBL] [Abstract][Full Text] [Related]
4. High plasma concentrations of paroxetine impede clinical response in patients with panic disorder.
Watanabe T; Ueda M; Saeki Y; Hirokane G; Morita S; Okawa M; Akiyama K; Shimoda K
Ther Drug Monit; 2007 Feb; 29(1):40-4. PubMed ID: 17304148
[TBL] [Abstract][Full Text] [Related]
5. Paroxetine, clomipramine, and cognitive therapy in the treatment of panic disorder.
Bakker A; van Dyck R; Spinhoven P; van Balkom AJ
J Clin Psychiatry; 1999 Dec; 60(12):831-8. PubMed ID: 10665629
[TBL] [Abstract][Full Text] [Related]
6. Double-blind, fixed-dose, placebo-controlled study of paroxetine in the treatment of panic disorder.
Ballenger JC; Wheadon DE; Steiner M; Bushnell W; Gergel IP
Am J Psychiatry; 1998 Jan; 155(1):36-42. PubMed ID: 9433336
[TBL] [Abstract][Full Text] [Related]
7. Panic disorder and dissociation - comparison with healthy controls.
Pastucha P; Prasko J; Grambal A; Latalova K; Sigmundova Z; Sykorova T; Tichackova A
Neuro Endocrinol Lett; 2009; 30(6):774-8. PubMed ID: 20038926
[TBL] [Abstract][Full Text] [Related]
8. Effects of gradual discontinuation of selective serotonin reuptake inhibitors in panic disorder with agoraphobia.
Fava GA; Bernardi M; Tomba E; Rafanelli C
Int J Neuropsychopharmacol; 2007 Dec; 10(6):835-8. PubMed ID: 17224089
[TBL] [Abstract][Full Text] [Related]
9. SECOND-STAGE TREATMENTS FOR RELATIVE NONRESPONDERS TO COGNITIVE BEHAVIORAL THERAPY (CBT) FOR PANIC DISORDER WITH OR WITHOUT AGORAPHOBIA-CONTINUED CBT VERSUS SSRI: A RANDOMIZED CONTROLLED TRIAL.
Payne LA; White KS; Gallagher MW; Woods SW; Shear MK; Gorman JM; Farchione TJ; Barlow DH
Depress Anxiety; 2016 May; 33(5):392-9. PubMed ID: 26663632
[TBL] [Abstract][Full Text] [Related]
10. Cognitive factors in panic disorder, agoraphobic avoidance and agoraphobia.
Berle D; Starcevic V; Hannan A; Milicevic D; Lamplugh C; Fenech P
Behav Res Ther; 2008 Feb; 46(2):282-91. PubMed ID: 18191103
[TBL] [Abstract][Full Text] [Related]
11. Does 5-HT restrain panic? A tryptophan depletion study in panic disorder patients recovered on paroxetine.
Bell C; Forshall S; Adrover M; Nash J; Hood S; Argyropoulos S; Rich A; Nutt DJ
J Psychopharmacol; 2002 Mar; 16(1):5-14. PubMed ID: 11949771
[TBL] [Abstract][Full Text] [Related]
12. Sertraline versus paroxetine in the treatment of panic disorder: an acute, double-blind noninferiority comparison.
Bandelow B; Behnke K; Lenoir S; Hendriks GJ; Alkin T; Goebel C; Clary CM
J Clin Psychiatry; 2004 Mar; 65(3):405-13. PubMed ID: 15096081
[TBL] [Abstract][Full Text] [Related]
13. Predictors of outcome of pharmacological and psychological treatment of late-life panic disorder with agoraphobia.
Hendriks GJ; Keijsers GP; Kampman M; Hoogduin CA; Oude Voshaar RC
Int J Geriatr Psychiatry; 2012 Feb; 27(2):146-50. PubMed ID: 21452176
[TBL] [Abstract][Full Text] [Related]
14. A naturalistic long-term comparison study of selective serotonin reuptake inhibitors in the treatment of panic disorder.
Dannon PN; Iancu I; Lowengrub K; Gonopolsky Y; Musin E; Grunhaus L; Kotler M
Clin Neuropharmacol; 2007; 30(6):326-34. PubMed ID: 18090457
[TBL] [Abstract][Full Text] [Related]
15. Olanzapine augmentation in panic disorder: a case report.
Chao I
Pharmacopsychiatry; 2004 Sep; 37(5):239-40. PubMed ID: 15470803
[TBL] [Abstract][Full Text] [Related]
16. Heightened embarrassability discriminates between panic disorder patients with and without agoraphobia.
Swoboda H; Demal U; Krautgartner M; Amering M
J Behav Ther Exp Psychiatry; 2003; 34(3-4):195-204. PubMed ID: 14972667
[TBL] [Abstract][Full Text] [Related]
17. Fear of Fear and Broad Dimensions of Psychopathology over the Course of Cognitive Behavioural Therapy for Panic Disorder with Agoraphobia in Japan.
Ogawa S; Kondo M; Ino K; Ii T; Imai R; Furukawa TA; Akechi T
East Asian Arch Psychiatry; 2017 Dec; 27(4):150-5. PubMed ID: 29259145
[TBL] [Abstract][Full Text] [Related]
18. A randomized, double-blind, placebo-controlled study of the effects of adjunctive paroxetine in panic disorder patients unsuccessfully treated with cognitive-behavioral therapy alone.
Kampman M; Keijsers GP; Hoogduin CA; Hendriks GJ
J Clin Psychiatry; 2002 Sep; 63(9):772-7. PubMed ID: 12363116
[TBL] [Abstract][Full Text] [Related]
19. Three year naturalistic outcome study of panic disorder patients treated with paroxetine.
Dannon PN; Iancu I; Cohen A; Lowengrub K; Grunhaus L; Kotler M
BMC Psychiatry; 2004 Jun; 4():16. PubMed ID: 15191617
[TBL] [Abstract][Full Text] [Related]
20. Selective serotonin reuptake inhibitors in the treatment of panic disorder and agoraphobia.
Bakker A; van Balkom AJ; van Dyck R
Int Clin Psychopharmacol; 2000 Aug; 15 Suppl 2():S25-30. PubMed ID: 11110016
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
